Drug Profile
Research programme: antibacterials - RecombinoGen
Alternative Names: Rumycin 1; Rumycin 2Latest Information Update: 18 Jan 2011
Price :
$50
*
At a glance
- Originator RecombinoGen
- Class Cyclic peptides; Lipoproteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 04 Dec 2007 This research programme is available for licensing worldwide (http://www.recombinogen.com)